HK1119950A1 - Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4- - Google Patents

Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4-

Info

Publication number
HK1119950A1
HK1119950A1 HK08113909.5A HK08113909A HK1119950A1 HK 1119950 A1 HK1119950 A1 HK 1119950A1 HK 08113909 A HK08113909 A HK 08113909A HK 1119950 A1 HK1119950 A1 HK 1119950A1
Authority
HK
Hong Kong
Prior art keywords
formulations
prevention
treatment
breast cancer
hydroxy tamoxifen
Prior art date
Application number
HK08113909.5A
Other languages
English (en)
Chinese (zh)
Inventor
Dominique Salin-Drouin
Jacques Wepierre
Philippe Rouanet
Original Assignee
Besins Healthcare Lu Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Healthcare Lu Sarl filed Critical Besins Healthcare Lu Sarl
Publication of HK1119950A1 publication Critical patent/HK1119950A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK08113909.5A 2003-04-01 2006-06-28 Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4- HK1119950A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45896303P 2003-04-01 2003-04-01

Publications (1)

Publication Number Publication Date
HK1119950A1 true HK1119950A1 (en) 2009-03-20

Family

ID=33131847

Family Applications (2)

Application Number Title Priority Date Filing Date
HK06107310.2A HK1086193A1 (en) 2003-04-01 2006-06-28 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4-
HK08113909.5A HK1119950A1 (en) 2003-04-01 2006-06-28 Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4-

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK06107310.2A HK1086193A1 (en) 2003-04-01 2006-06-28 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4-

Country Status (12)

Country Link
US (2) US7704516B2 (ja)
EP (3) EP1952810B1 (ja)
JP (1) JP5490346B2 (ja)
AU (1) AU2003294973B2 (ja)
CA (1) CA2519980C (ja)
ES (3) ES2483896T3 (ja)
HK (2) HK1086193A1 (ja)
IL (1) IL170807A (ja)
MX (1) MXPA05010597A (ja)
NO (1) NO333805B1 (ja)
NZ (1) NZ542499A (ja)
WO (1) WO2004087123A1 (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4938237B2 (ja) * 2002-12-18 2012-05-23 ラボラトワール ブザン アンテルナスィヨナル ４−ヒドロキシタモキシフェンによる乳房痛の治療
EP1952809B1 (en) * 2002-12-18 2017-08-02 Besins Healthcare Luxembourg SARL Formulations for the reduction of breast density with 4-Hydroxy Tamoxifen
JP5490346B2 (ja) * 2003-04-01 2014-05-14 ブザン ヘルスケア ルクセンブルグ エスアーエールエル ４−ヒドロキシタモキシフェンによる乳癌の予防および治療
DE602004013439T2 (de) * 2003-06-09 2009-06-04 Ascend Therapeutics, Inc. Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
AU2005227072B2 (en) * 2004-03-22 2010-08-19 Besins Healthcare Luxembourg Sarl Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
EP1579856A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
DK1799201T3 (da) * 2004-10-14 2009-03-30 Besins Int Lab 4-Hydroxy-tamoxifen gelformuleringer
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
CA2948823C (en) 2014-05-12 2020-09-22 Quest Diagnostics Investments Incorporated Quantitation of tamoxifen and metabolites thereof by mass spectrometry
KR101571098B1 (ko) 2014-07-16 2015-11-23 건국대학교 산학협력단 타목시펜 및 메틸설포닐메탄을 유효성분으로 포함하는 암 질환 예방 또는 치료용 약학 조성물
WO2016031342A1 (ja) * 2014-08-27 2016-03-03 東洋紡株式会社 低誘電接着剤組成物
WO2016094854A2 (en) * 2014-12-12 2016-06-16 Miradx Methods for treating or preventing cancer in a kras-variant patient and for diagnosing risk of developing multiple primary breast tumors
JP7131773B2 (ja) * 2016-04-29 2022-09-06 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ホルモン受容体に関連する転写活性の標的尺度
SG11202002105WA (en) 2017-09-11 2020-04-29 Atossa Therapeutics Inc Methods for making and using endoxifen
WO2019172109A1 (ja) 2018-03-07 2019-09-12 東亞合成株式会社 接着剤組成物及びこれを用いた接着剤層付き積層体
WO2020023616A1 (en) * 2018-07-24 2020-01-30 Cornell University Methods of upregulating tiparp as anticancer strategies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
ES2044860T3 (es) * 1987-04-21 1994-01-16 Heumann Pharma Gmbh & Co Estables aductos con disolventes de z-1-(p-beta-di-metil-amino-etoxi-fenil)-1-(p-hidroxi-fenil)-2-fenil-but-1-eno.
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
US5189212A (en) * 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
TW218849B (ja) * 1991-05-17 1994-01-11 Bristol Myers Squibb Co
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
DE4407742C1 (de) 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
WO1997036570A1 (de) * 1996-03-29 1997-10-09 S.W. Patentverwertungs Ges. M.B.H. Edelsbacher U. Partner Kosmetikum bzw. kosmetikzusammensetzung zur glättung und straffung der haut bei gestörtem unterhaut-binde-fettgewebe, insbesondere bei der 'cellulite'
WO1999033451A2 (en) 1997-12-23 1999-07-08 Hexal Ag Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
MXPA02006055A (es) 1999-12-16 2004-08-23 Dermatrends Inc Agentes liberadores de hidroxido como incrementadores de penetracion en la piel.
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
AU2002340120A1 (en) * 2001-10-04 2003-04-14 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
DE60139625D1 (de) * 2001-12-07 2009-10-01 Besins Int Belgique Gel oder Lösung enthaltend Dihydrotestosterone, deren Herstellungsverfahren und Verwendung
JP4938237B2 (ja) * 2002-12-18 2012-05-23 ラボラトワール ブザン アンテルナスィヨナル ４−ヒドロキシタモキシフェンによる乳房痛の治療
EP1952809B1 (en) * 2002-12-18 2017-08-02 Besins Healthcare Luxembourg SARL Formulations for the reduction of breast density with 4-Hydroxy Tamoxifen
JP5490346B2 (ja) * 2003-04-01 2014-05-14 ブザン ヘルスケア ルクセンブルグ エスアーエールエル ４−ヒドロキシタモキシフェンによる乳癌の予防および治療
DE602004013439T2 (de) * 2003-06-09 2009-06-04 Ascend Therapeutics, Inc. Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
EP1579856A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations

Also Published As

Publication number Publication date
ES2456957T3 (es) 2014-04-24
ES2483896T3 (es) 2014-08-08
WO2004087123A1 (en) 2004-10-14
NO333805B1 (no) 2013-09-16
NO20054526L (no) 2005-09-30
EP1941871B1 (en) 2014-01-08
CA2519980C (en) 2012-04-10
CA2519980A1 (en) 2004-10-14
EP1941871A1 (en) 2008-07-09
US8475814B2 (en) 2013-07-02
AU2003294973B2 (en) 2010-05-13
NZ542499A (en) 2008-10-31
IL170807A (en) 2014-08-31
US20050031695A1 (en) 2005-02-10
MXPA05010597A (es) 2006-03-09
EP1952810A1 (en) 2008-08-06
JP5490346B2 (ja) 2014-05-14
JP2006514967A (ja) 2006-05-18
ES2456958T3 (es) 2014-04-24
US7704516B2 (en) 2010-04-27
AU2003294973A1 (en) 2004-10-25
HK1086193A1 (en) 2006-09-15
EP1608353B1 (en) 2014-04-30
US20090186944A1 (en) 2009-07-23
EP1952810B1 (en) 2014-01-08
EP1608353A1 (en) 2005-12-28

Similar Documents

Publication Publication Date Title
HK1119950A1 (en) Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4-
EP1816996A4 (en) THERAPEUTIC METHODS AND COMPOSITIONS COMPRISING PLANT EXTRACTS FOR THE TREATMENT OF CANCER
EP1663259A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP1872124A4 (en) DIAGNOSTIC MARKERS FOR THE TREATMENT AND EVOLUTION OF BREAST CANCER AND METHODS OF USE
EP1968607A4 (en) TREATMENT OF CANCER AND OTHER DISEASES
EP1812596A4 (en) TREATMENT OF CANCER AND COMPOSITIONS
IL166475A0 (en) Improved treatment of cancer with glutamine
EP1667680A4 (en) COMBINED METHODS OF TREATING CANCER
HK1204476A1 (en) Compounds and methods for treatment of cancer
IL181304A0 (en) Dihydropteridinones for the treatment of cancer diseases
EP1756166A4 (en) DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
EP1583536A4 (en) METHOD OF TREATING PROSTATIC CANCER AND COMPOSITION FOR TREATMENT THEREOF
HK1125038A1 (en) Iontophoresis preparation for treatment of breast cancer and/or mastitis
ZA200510282B (en) Compositions and methods for the diagnosis and treatment of tumor
IL158206A0 (en) Compositions and methods for the prevention and treatment of human prostate cancer
IL145397A0 (en) Compositions and methods for treatment of cancer
EP1420814A4 (en) COMPOSITIONS AND TECHNIQUES FOR THERAPY AND DIAGNOSIS OF BREAST CANCER
AU2003237792A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1904088A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP1797430A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER
AU2003293130A8 (en) Methods for identifying risk of breast cancer and treatments thereof
AU2003231803A8 (en) Treatment of cancer with mefloquire
GB0329416D0 (en) Treatment of cancer
EP1684795A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF CANCER
EP1583543A4 (en) METHOD AND THERAPEUTIC COMPOSITIONS IN THE TREATMENT OF ADVANCED CARCINOMA

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20231216